+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor IX"

Hemophilia Treatment Market - Global Forecast 2026-2032 - Product Thumbnail Image

Hemophilia Treatment Market - Global Forecast 2026-2032

  • Report
  • August 2026
  • 190 Pages
  • Global
From
From
From
Hemophilia Drugs - Global Strategic Business Report - Product Thumbnail Image

Hemophilia Drugs - Global Strategic Business Report

  • Report
  • August 2026
  • 196 Pages
  • Global
From
From
Prothrombin Complex Concentrate Market Report 2026 - Product Thumbnail Image

Prothrombin Complex Concentrate Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
Coagulation Factor Deficiency Market Report 2026 - Product Thumbnail Image

Coagulation Factor Deficiency Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Synthetic Blood Substitutes and Blood Products Market Report 2026 - Product Thumbnail Image

Synthetic Blood Substitutes and Blood Products Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Hemophilia B - Pipeline Insight, 2026 - Product Thumbnail Image

Hemophilia B - Pipeline Insight, 2026

  • Clinical Trials
  • May 2026
  • 80 Pages
  • Global
From
Loading Indicator

Factor IX is a protein used to treat hemophilia B, a rare genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of the human factor IX protein, which is produced in a laboratory setting. Factor IX is administered intravenously or subcutaneously to replace the missing clotting factor in patients with hemophilia B. It is used to prevent and treat bleeding episodes, as well as to prevent bleeding during surgery. Factor IX is a part of the larger hematological drugs market, which includes drugs used to treat blood-related diseases and disorders. These drugs are used to treat a wide range of conditions, including anemia, leukemia, and thrombocytopenia. Some companies in the Factor IX market include Novo Nordisk, Pfizer, Bayer, and Biogen. Show Less Read more